FDA Clearance Tracker · P150013-S001
PD-L1 IHC 22C3 PHARMDX
Last checked: Nov 20, 2026Latest source record: Oct 24, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Oct 24, 2016
Approved
Time to decision
298 days
Received Dec 31, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150013-S001
- Device name
- PD-L1 IHC 22C3 PHARMDX
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Dec 31, 2015
- Decided
- Oct 24, 2016
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Original approval
- P150013
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS greater than or equal to 1% and high PD-L1 expression if TPS is greater than or equal to 50%. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances. This device is for in vitro diagnostic use.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.